Platinum Chemotherapy: vs. Temozolomide/Capecitabine for Advanced GEPNENs: ECOG-ACRIN EA2142 Results Jennifer Eads MD - Synopsis below extracted from the video transcript.
Dr. Jennifer Eads from the Penn Medicine discusses the results of the ECOG-ACRIN EA2142 trial, which compared platinum-based chemotherapy to temozolomide/capecitabine for the treatment of advanced gastroesophageal junction (GEJ) and gastric adenocarcinoma.
The clinical trial included 385 patients who had advanced GEJ or gastric adenocarcinoma that had not been treated in the past. These patients were randomly assigned to undergo either chemotherapy based on platinum or temozolomide/capecitabine. The major objective was to determine the overall survival (OS) rate.
The results showed that there was no significant difference in OS between the two treatment groups, with a median OS of 10.5 months in the platinum-based chemotherapy group and 9.3 months in the temozolomide/capecitabine group. However, there was a statistically significant difference in progression-free survival (PFS) in favor of the platinum-based chemotherapy group, with a median PFS of 5.6 months compared to 4.2 months in the temozolomide/capecitabine group.
The frequency of adverse events was comparable across the two treatment groups in terms of safety, with neutropenia, anemia, and tiredness being the three adverse events that occurred more frequently than any of the others.
Dr. Eads further comments that the findings of this research are similar with the findings of prior studies, which demonstrated that chemotherapy based on platinum is a feasible choice for the treatment of advanced GEJ as well as gastric adenocarcinoma.
Overall, the ECOG-ACRIN EA2142 trial provides important insights into the comparative effectiveness and safety of platinum-based chemotherapy and temozolomide/capecitabine for the treatment of advanced GEJ and gastric adenocarcinoma, and underscores the need for further research in this area.
